Partner, Venrock
Camille “Cami” Samuels is a partner at Venrock, one of the world’s original venture firms. Her focus is early-stage healthcare with an emphasis on biotech, medical devices and consumer health. She currently serves on the boards of Cavalry, Iris, Mahzi, and Unity. She previously served on the board of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio and Spirox (now owned by Stryker). Prior to Venrock, Cami was a managing director at Versant Ventures where she served on the board or as a board observer at Genomic Health (sold to Exact), Jazz, Kythera (sold to Allergan) and Novacardia (sold to Merck) among many others. During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK. Cami earned her bachelor’s degree in biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar. She is a Henry Crown Fellow, serves on the Investment Advisory Committee of Mission BioCapital as well as Jupiter, and serves on the HBS Global Advisory Board.